| [1] |
Boss MK, Muradyan N, Thrall DE. DCE-MRI: a review and applications in veterinary oncology[J]. Vet Comp Oncol, 2013, 11(2): 87-100.
|
| [2] |
Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker[J]. J Clin Oncol, 2006, 24(20): 3293-8.
|
| [3] |
Hillman GG, Singh-Gupta V, Al-Bashir AK, et al. Dynamic contrast- enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors[J]. Transl Oncol, 2010, 3(5): 293-306.
|
| [4] |
Agner SC, Rosen MA, Englander SA, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced Mr images: a feasibility study[J]. Radiology, 2014, 272(1): 91-9.
|
| [5] |
Türkbey B, Thomasson D, Pang Y, et al. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment[J]. Diagn Interv Radiol, 2010, 16(3): 186-92.
|
| [6] |
Nci C. 5-Tesla and endpoints for use in phase 1/2a trials of anticancer therapeutics affecting tumor vascular function,MR workshop on translational research in cancer:recommendations for MR measurement methods at 1[R], 2008: 1-10.
|
| [7] |
Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA Mr imaging [J]. J Magn Reson Imaging, 1997, 7(1): 91-101.
|
| [8] |
Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging[J]. Magn Reson Med, 2004, 51(4): 858-62.
|
| [9] |
Sourbron SP, Buckley DL. Classic models for dynamic contrast-enhanced MRI[J]. NMR Biomed, 2013, 26(8, SI): 1004-27.
|
| [10] |
Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging[J]. J Magn Reson Imaging, 2003, 17(5): 509-20.
|
| [11] |
Tuncbilek N, Tokatli F, Altaner S, et al. Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients[J]. Eur J Radiol, 2012, 81(5): 863-7.
|
| [12] |
El Khouli RH, Macura KJ, Jacobs MA, et al. Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment[J]. AJR Am J Roentgenol, 2009, 193 (4):W295-300.
|
| [13] |
Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging[J]. Cancer Res, 2008, 68(16): 6598-607.
|
| [14] |
]Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J]. J Clin Oncol, 2006, 24(5): 769-77.
|
| [15] |
Padhani AR, Khan AA. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy[J]. Target Oncol, 2010, 5(1): 39-52.
|
| [16] |
Edelman RR, M AM, Atkinson DJ, et al. C erebral blood flow: assessment with dynamic contrast-enhanced T2*WI Mr imaging at 1.5T[J]. Radiology, 1990, 176(1): 211-20.
|
| [17] |
Simonsen CZ, Ostergaard L, Smith DF, et al. Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking[J]. J Magn Reson Imaging, 2000, 12(3): 411-6.
|
| [18] |
Ichikawa T, SaitoK,YoshiokaN, et al. Detection and characterization of focal liver lesions a Japanese phase III, multicenter comparison between gadoxetic acid disodium-Enhanced magnetic resonance imaging and Contrast-enhanced computed tomography predominantly in patients with hepatocellular[J]. Invest Radiol, 2010, 45(3): 133-41.
|
| [19] |
Kuhl CK. MRI of breast tumors[J]. Eur Radiol, 2000, 10(1): 46-58.
|
| [20] |
Kvistad KA, Rydland J, Vainio J, et al. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted Mr imaging and with T2*-weighted first-pass perfusion Mr imaging[J]. Radiology, 2000, 216(2): 545-53.
|
| [21] |
Knopp MV, Junkermann H, Sinn HP. Monstrous breast tumor[J]. Radiologe, 1995, 35(5): 363-6.
|
| [22] |
Reiners KS, Gossmann A, Von Strandmann EP, et al. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma[J]. J Immunother, 2009, 32(5): 508-12.
|
| [23] |
Ibrahim MA, Haughton VM, Hyde JS. Enhancement of intervertebral disks with Gadolinium complexes: comparison of an Ionic and a nonionic medium in an animal model[J]. AJNR Am J Neuroradiol, 1994, 15(10): 1907-10.
|
| [24] |
Ibrahim MA, Jesmanowicz A, Hyde JS, et al. Contrast enhancement of normal intervertebral disks: time and dose dependence[J]. AJNR Am J Neuroradiol, 1994, 15(3): 419-23.
|
| [25] |
Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced Mr imaging [J]. Radiology, 2003, 229(1): 248-54.
|
| [26] |
Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer[J]. NMR Biomed, 2009, 22(1): 28-39.
|
| [27] |
Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic Contrast-Enhanced MRI in prostate cancer diagnosis and management [J]. AJR Am J Roentgenol, 2012, 198(6): 1277-88.
|
点击查看大图
下载:
